Eliminate the guesswork from your breast cancer patient management with Falcon Genomics’ Cancer BioChip System.
The FALCON Breast Cancer Test (BCT) and the FALCON Tamo Test provide the answers patients and clinicians need to accurately diagnose and treat breast cancer.
This is the most Comprehensive Breast Cancer Classifier. It identifies 8 breast cancer classes instead of the currently used 4 classes.
The TAMO test is specifically designed to determine whether Tamoxifen therapy will be effective. It is used to identify patients that do not benefit from Tamoxifen therapy at diagnosis and eliminates side effects of long-term ineffective therapy.
For patients with tumors that do not respond to current therapy, eliminate the trial-an-error, by screening for targeted and efficient therapies using the Cancer BioChip System.
Falcon Genomics received Notice of Allowance for its patent application No.13/441,855, titled "Systems and Methods for Individualized Functional Genomic Profiling Related to Cancer Cell Growth".
Falcon Genomics received its Clinical Laboratory Permit from the State of Pennsylvania.
October 13, 2014
Mr. Dana E. Thomas presents Falcon Genomics' Company Presentation at Life Sciences Future, Philadelphia, PA
July 29, 2014
Dr. Rula Abbud-Antaki receives 2 awards at the AACC 2014 Annual Meeting and Clinical Lab Expo for her poster presentation on the Falcon Breast Cancer Test, titled: "Identification of four molecular subclasses of Luminal Breast Cancer with Different likelihood of recurrence and response to Tamoxifen".
May 17, 2013
Falcon Genomics, Inc. receives notice of allowance for its Canadian Patent Application # 2,593,494.